Skip to main content

Advertisement

SpringerLink
Log in

Decade in review—HCV

Hepatitis C therapy—a fast and competitive race

  • News & Views
  • Published:

From Nature Reviews Gastroenterology & Hepatology

View current issue Sign up to alerts

The past 10 years have witnessed incredible developments in the treatment of hepatitis C. From an era in which the standard of care was PEG-IFN and ribavirin back in 2004, various interferon-free regimens with direct-acting antivirals are now available or will be soon. Here, major milestones in the hepatitis C treatment revolution are outlined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lange, C. M., Jacobson, I. M., Rice, C. M. & Zeuzem, S. Emerging therapies for the treatment of hepatitis C. EMBO Mol. Med. 6, 4–15 (2014).

    Article  CAS  Google Scholar 

  2. Lamarre, D. et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426, 186–189 (2003).

    Article  CAS  Google Scholar 

  3. Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399–401 (2009).

    Article  CAS  Google Scholar 

  4. Gane, E. J. et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 368, 34–44 (2013).

    Article  CAS  Google Scholar 

  5. Lok, A. S. et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 366, 216–224 (2012).

    Article  CAS  Google Scholar 

  6. Afdhal, N. et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med. 370, 1889–1898 (2014).

    Article  Google Scholar 

  7. Afdhal, N. et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med. 370, 1483–1493 (2014).

    Article  CAS  Google Scholar 

  8. Feld, J. J. et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 370, 1594–1603 (2014).

    Article  CAS  Google Scholar 

  9. Zeuzem, S. et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 370, 1604–1614 (2014).

    Article  CAS  Google Scholar 

  10. Zeuzem, S. Faldaprevir and deleobuvir for HCV genotype 1 infection. N. Engl. J. Med. 369, 630–639 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, J. W. Goethe University Hospital, Theodor-Stern-Kai 7, Frankfurt am Main, 60590, Germany

    Stefan Zeuzem

Authors
  1. Stefan Zeuzem
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan Zeuzem.

Ethics declarations

Competing interests

The author acts as a consultant for Abbvie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Idenix, Janssen, Merck, Novartis, Roche, Santaris and Vertex. He is a member of the speakers' bureau for Abbvie, Bristol-Myers Squibb, Gilead, Janssen, Merck and Roche.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zeuzem, S. Hepatitis C therapy—a fast and competitive race. Nat Rev Gastroenterol Hepatol 11, 644–645 (2014). https://doi.org/10.1038/nrgastro.2014.164

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2014.164

  • Springer Nature Limited

This article is cited by

Search

Navigation